This inventor holds 2 USPTO granted patents. Top assignees: Risen (Suzhou) Pharma Tech Co., Ltd., Risen (Suzhou) Pharma Tech Co., Ltd.. Active years: 2021-2026.
Company Filing History:
1 out of 16 
1 out of 4 Years Active: 2021-2026
Title: Chengyong Sun: Innovator in CD73 Inhibitors
Introduction
Chengyong Sun is a prominent inventor based in Suzhou, China. He has made significant contributions to the field of pharmaceuticals, particularly in the development of CD73 inhibitors. His work focuses on innovative solutions for treating various diseases, including cancer and immune-related disorders.
Latest Patents
Chengyong Sun holds a patent for "CD73 inhibitors and pharmaceutical uses thereof." This patent includes compounds that inhibit CD73, also known as ecto-5'-nucleotidase. The compounds provided in this patent are designed for treating or preventing CD73-associated diseases, disorders, and conditions. These include cancer- and immune-related disorders. The patent outlines compounds with a specific structure, as well as their pharmaceutically acceptable esters or salts.
Career Highlights
Chengyong Sun is currently associated with Risen (Suzhou) Pharma Tech Co., Ltd. His role in the company allows him to further his research and development efforts in the pharmaceutical industry. His innovative work has positioned him as a key figure in the advancement of therapeutic options for patients.
Collaborations
Chengyong Sun collaborates with notable colleagues, including Feng Zhou and Gang Chen. These partnerships enhance the research and development process, fostering innovation in the field of pharmaceuticals.
Conclusion
Chengyong Sun's contributions to the development of CD73 inhibitors represent a significant advancement in the treatment of various diseases. His work continues to impact the pharmaceutical industry positively, paving the way for new therapeutic options.